Addressing the Biotech Valley of Death as a Systemic Market Failure

The episode argues that the biotech "valley of death" is a systemic market failure rather than a simple lack of startup funding. It suggests that moving from laboratory success to industrial production requires specialized infrastructure that behaves more like a public utility than a typical private asset. Because venture capital is often poorly suited for the high costs and long timelines of bioprocess scale-up, the author advocates for shared pilot facilities and milestone-based public funding. These interventions aim to preserve technical know-how and domestic manufacturing capability, even when individual companies struggle. Ultimately, the discussion promotes shifting policy focus from individual startup survival toward building durable industrial sovereignty through coordinated investment and adaptive governance.

#Bioprocess #ScaleUp and #TechTransfer,
#Industrial #Microbiology,
#MetabolicEngineering and #SystemsBiology,
#Bioprocessing,
#MicrobialFermentation,
#Bio-manufacturing,
#Industrial #Biotechnology,
#Fermentation Engineering,
#ProcessDevelopment,
#Microbiology, #Biochemistry
#Biochemical Engineering,
#Applied #MicrobialPhysiology,
#Microbial #ProcessEngineering,
#Upstream #BioprocessDevelopment,
#Downstream Processing and #Purification,
#CellCulture and #MicrobialSystems Engineering,
#Bioreaction #Enzymes
#Biocatalyst
#scientific
#Scientist
#Research